Jun 2026 (Q2 FY26) — Aug 5, 2026
Caris Life Sciences Q2 FY26 — Record Clinical Volume and Strong Financials Drive Raised Outlook
Read the full callCaris Life Sciences (CAI) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Caris Life Sciences earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 264 | +45.4% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 10.2 | +20.1 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -0.64 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$30.71 +0.49% · +$0.15
Performance −2.5% 1Y
1Y: $31.5 on 17 Oct 2025 → $30.71. High $32.27 (24 Sept 2026), low $14.55 (15 May 2026).
- Previous close
- $30.56
- 52-week range
- $14.55 – $32.27
- One year
- −2.51%
Overview
- Symbol
- CAI
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Mar 2026 (Q1 FY26) — May 7, 2026
Caris Life Sciences Q1 FY26 — Strong Revenue Growth and Profitability Driven by Molecular Profiling
Read the full callDec 2025 (Q4 FY25) — Feb 26, 2026
Caris Life Sciences Q4 FY25 — Record Revenue, Strong Profitability, and Early Detection Progress
Read the full callEvery analysed call
Caris Life Sciences earnings calls (CAI)
Financials
What the filings say
Net profit, year on year: +99% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 102 | 130 | 121 | 181 | 217 | 293 | 216 | 264 |
| Expenses | 162 | 167 | 179 | 199 | 184 | 204 | 211 | 237 |
| Operating profit | -61 | -37 | -58 | -18 | 33 | 88 | 5 | 27 |
| Operating margin | −59.9% | −28.5% | −47.9% | −9.9% | 15.1% | 30.2% | 2.4% | 10.2% |
| Other income | -7 | 0 | -45 | -54 | -8 | -6 | -6 | -28 |
| Interest | 14 | 13 | 13 | 19 | 14 | 11 | 13 | 9 |
| Profit before tax | -68 | -37 | -103 | -72 | 24 | 82 | -1 | -1 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 20.8% | −3.8% |
| Net profit | -68 | -37 | -103 | -72 | 24 | 82 | -1 | -1 |
| EPS ($ per share) | -2.59 | — | -3.57 | -7.97 | 0.09 | — | 0 | 0 |
| Line item | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Equity capital | — | 0 | 0 |
| Reserves | — | -2,472 | -2,549 |
| Total liabilities | — | 621 | 548 |
| Fixed assets | — | 68 | 63 |
| Investments | — | 2 | 2 |
| Total assets | — | 344 | 1,126 |
| Line item | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Cash from operations | -276 | -245 | 83 |
| Cash from investing | 215 | 53 | -16 |
| Cash from financing | 10 | 200 | 665 |
| Net cash flow | -51 | 8 | 732 |
| Capital expenditure | -22 | -8 | -16 |
| Free cash flow | -298 | -254 | 67 |
CAI revenue by segment
| Segment | Q2 FY2025 | Q3 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|
| Pharma Research and Development Services | — | — | 2% | 4% | — |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
CAI operating KPIs by quarter
| KPI | Dec 2025 Q4 FY25 | Mar 2026 Q1 FY26 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|---|
| Covered lives MI Cancer Seek | 225M+The key driver for tissue was obviously the impact from our FDA approval and the subsequent increase in pricing and the benefits we saw through contract, where we have now surpassed over 225 million covered lives from MI Cancer Seek.Source: earnings call transcript | 225M+At this point, we're above $225 million covered lives for MI Cancer Seek, which we expect to continue to increase throughout the course of this year, and the assay represented more than 75% of our tissue volume in Q1.Source: earnings call transcript | ~239.5MWith regard to covered lives that now stands at approximately $239.5 million for MI Cancer Seq and $131.9 million for Care Assure and is a testament to the great work by our market access teams as we continue to see improvements across the payer landscape.Source: earnings call transcript | — |
| Procedures | — | 52.8KIn the first quarter, we completed 52,800 cases, up 15% year-over-year.Source: earnings call transcript | 59.2KWe added roughly 6,400 cases in the quarter, a record for sequential case additions that led us to 59,200 cases.Source: earnings call transcript | +12.1% |
| Procedures Tissue | — | ~43.6KFor Q1 overall, we completed approximately 52,800 therapy selection cases, up 15% year-over-year, including approximately 43,600 tissue cases and approximately 9,200 Caris Assure cases.Source: earnings call transcript | ~48.3KWith respect to performance by product, we completed approximately 48,300 MI profile tissue cases, up 13% year-over-year and 11% sequentially and 10,700 Caris Assure blood cases up 50% year-over-year and 17% sequentially.Source: earnings call transcript | — |
| Procedures Caris Assure | — | ~9,200For Q1 overall, we completed approximately 52,800 therapy selection cases, up 15% year-over-year, including approximately 43,600 tissue cases and approximately 9,200 Caris Assure cases.Source: earnings call transcript | 10.7KWith respect to performance by product, we completed approximately 48,300 MI profile tissue cases, up 13% year-over-year and 11% sequentially and 10,700 Caris Assure blood cases up 50% year-over-year and 17% sequentially.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Revenue by region
Q2 FY2026 · share of revenue
- Non Us 1% ↓ 1 pt
As CAI cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
45 filings between Nov 7, 2025 and Sep 22, 2026.
Open market
decisions to buy or sellPurchases
$1.60M
4 purchases by 4 insiders
Sales
$28.86M
7 sales by 4 insiders
29% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 21
- Award — granted as compensation
- 6
- Option exercise — converted options into shares
- 5
- Tax withheld — shares kept back by the company to cover tax
Also filed: 2 gifts.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Spetzler David Baxley | $9.5K | $14.83M | Sep 4, 2026 |
| Brille Brian J | — | $12.13M | Sep 17, 2026 |
| Power Luke Thomas | — | $1.65M | Dec 11, 2025 |
| HALBERT JON | $990.1K | — | May 15, 2026 |
| Vacirca Jeff L | $501.4K | — | May 11, 2026 |
| Denton John Russel | $100.8K | $238.6K | Sep 22, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 22, 2026 | Denton John Russel See Remarks | Sale | 7,500 | $238.6K |
| Sep 17, 2026 | Brille Brian J See Remarks | Option exercise | 400,000 | $976.0K |
| Sep 17, 2026 | Brille Brian J See Remarks | Sale | 400,000 | $12.13M |
| Sep 4, 2026 | Spetzler David Baxley President | Sale | 119,212 | $2.95M |
| Sep 4, 2026 | Spetzler David Baxley President | Option exercise | 250,000 | $610.0K |
| Sep 3, 2026 | Spetzler David Baxley President | Sale | 84,900 | $2.15M |
| Sep 3, 2026 | Spetzler David Baxley President | Sale | 393,100 | $9.73M |
| Sep 3, 2026 | Spetzler David Baxley President | Option exercise | 1,000,000 | $2.44M |
| Aug 14, 2026 | Vacirca Jeff L Director | Award | 13,192 | $0 |
| Aug 14, 2026 | Minor Lloyd Director | Award | 13,192 | $0 |
| Aug 14, 2026 | Fredrickson David Paul Director | Award | 13,192 | $0 |
| Aug 14, 2026 | JOHANSEN LAURA I Director | Award | 13,192 | $0 |
| Aug 14, 2026 | CASTLEMAN PETER M Director | Award | 13,192 | $0 |
| Aug 14, 2026 | HALBERT JON Director | Award | 13,192 | $0 |
| Aug 14, 2026 | PHILLIPS T DANNY Director | Award | 13,192 | $0 |
| Aug 14, 2026 | Gilliam Joseph E Director | Award | 13,192 | $0 |
| May 29, 2026 | Knowles Jonathan Kenneth Charles Director | Award | 1,600 | $25.0K |
| May 29, 2026 | POSTE GEORGE Director | Award | 1,600 | $25.0K |
| May 15, 2026 | HALBERT JON Director | Purchase | 68,000 | $990.1K |
| May 15, 2026 | Spetzler David Baxley President | Tax withheld | 13,856 | $211.3K |
| May 15, 2026 | Denton John Russel See Remarks | Tax withheld | 6,047 | $92.2K |
| May 15, 2026 | HALBERT DAVID D See Remarks | Tax withheld | 40,712 | $620.9K |
| May 15, 2026 | Brille Brian J See Remarks | Tax withheld | 13,987 | $213.3K |
| May 15, 2026 | Power Luke Thomas See Remarks | Tax withheld | 9,771 | $149.0K |
| May 11, 2026 | Vacirca Jeff L Director | Purchase | 31,050 | $501.4K |
| Mar 6, 2026 | Brille Brian J See Remarks | Award | 83,162 | $0 |
| Mar 6, 2026 | Power Luke Thomas See Remarks | Award | 63,971 | $0 |
| Mar 6, 2026 | HALBERT DAVID D See Remarks | Award | 320,112 | $0 |
| Mar 6, 2026 | Denton John Russel See Remarks | Award | 63,971 | $0 |
| Mar 6, 2026 | Spetzler David Baxley President | Award | 83,162 | $0 |
| Feb 26, 2026 | Minor Lloyd Director | Award | 2,492 | $50.0K |
| Feb 26, 2026 | PHILLIPS T DANNY Director | Award | 3,739 | $75.0K |
| Feb 26, 2026 | Vacirca Jeff L Director | Award | 2,492 | $50.0K |
| Feb 26, 2026 | Fredrickson David Paul Director | Award | 2,492 | $50.0K |
| Feb 26, 2026 | CASTLEMAN PETER M Director | Award | 5,509 | $110.5K |
| Feb 26, 2026 | HALBERT JON Director | Award | 2,492 | $50.0K |
| Jan 9, 2026 | CASTLEMAN PETER M Director | Option exercise | 2,500 | $46.5K |
| Dec 11, 2025 | Power Luke Thomas See Remarks | Sale 10b5-1 plan | 1,400 | $38.0K |
| Dec 11, 2025 | Brille Brian J See Remarks | Gift | 650 | $0 |
| Dec 11, 2025 | Power Luke Thomas See Remarks | Sale 10b5-1 plan | 60,850 | $1.62M |
| Dec 11, 2025 | Power Luke Thomas See Remarks | Option exercise 10b5-1 plan | 37,500 | $91.5K |
| Dec 11, 2025 | Power Luke Thomas See Remarks | Option exercise 10b5-1 plan | 24,750 | $60.4K |
| Dec 10, 2025 | Brille Brian J See Remarks | Gift | 650 | $0 |
| Nov 7, 2025 | Denton John Russel See Remarks | Purchase | 4,184 | $100.8K |
| Nov 7, 2025 | Spetzler David Baxley President | Purchase | 400 | $9.5K |
| Sep 11, 2025 | PHILLIPS T DANNY Director | Option exercise | 100,000 | $244.0K |
| Aug 11, 2025 | POSTE GEORGE Director | Option exercise | 125,000 | $305.0K |
| Aug 11, 2025 | HALBERT DAVID D See Remarks | Tax withheld | 141,956 | $4.22M |
| Aug 11, 2025 | Spetzler David Baxley President | Tax withheld | 63,509 | $1.89M |
| Aug 11, 2025 | POSTE GEORGE Director | Tax withheld | 48,022 | $1.43M |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Caris Life Sciences, Inc.
Free account. Everything above stays public.
Write why you follow Caris Life Sciences, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading